Search

Genfit

Chiusa

SettoreSettore sanitario

3.72 0.7

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.66

Massimo

3.734

Metriche Chiave

By Trading Economics

Entrata

19M

-10M

Vendite

28M

36M

P/E

Media del settore

104.267

37.461

Margine di Profitto

-28.017

Dipendenti

188

EBITDA

25M

955K

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+125.29% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

25M

189M

Apertura precedente

3.02

Chiusura precedente

3.72

Notizie sul Sentiment di mercato

By Acuity

29%

71%

62 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Genfit Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ott 2025, 18:41 UTC

Utili

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 ott 2025, 18:31 UTC

Utili

Correction to Procter & Gamble to Focus on Innovation

24 ott 2025, 16:25 UTC

I principali Market Mover

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 ott 2025, 21:24 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

24 ott 2025, 21:24 UTC

Discorsi di Mercato

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 ott 2025, 21:07 UTC

Utili

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 ott 2025, 20:58 UTC

Utili

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 ott 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

24 ott 2025, 20:40 UTC

Utili

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 ott 2025, 20:24 UTC

Utili

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 ott 2025, 20:23 UTC

Utili

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 ott 2025, 20:13 UTC

Utili

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 20:07 UTC

Discorsi di Mercato

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 ott 2025, 19:40 UTC

Discorsi di Mercato

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 ott 2025, 19:35 UTC

Discorsi di Mercato

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 ott 2025, 19:33 UTC

Utili

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 ott 2025, 19:29 UTC

Discorsi di Mercato

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 ott 2025, 18:52 UTC

Utili

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 ott 2025, 18:41 UTC

Utili

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 ott 2025, 18:03 UTC

Utili

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 ott 2025, 18:02 UTC

Utili

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 ott 2025, 18:00 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 ott 2025, 16:57 UTC

Utili

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 ott 2025, 16:54 UTC

Discorsi di Mercato

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 ott 2025, 16:44 UTC

Discorsi di Mercato
Utili

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 ott 2025, 16:39 UTC

Discorsi di Mercato
Utili

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 ott 2025, 16:33 UTC

Utili

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 16:23 UTC

Utili

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

24 ott 2025, 16:07 UTC

Utili

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Genfit Previsione

Obiettivo di Prezzo

By TipRanks

125.29% in crescita

Previsioni per 12 mesi

Media 8.403 EUR  125.29%

Alto 8.4 EUR

Basso 8.4 EUR

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Genfit - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

3.566 / 4.12Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

62 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
help-icon Live chat